careHPV® DNA Test-from China to the world
2002
WHO proposed the development of rapid HPV technology
2003-2007
START-UP project by Dr. Qiao's team and QIAGEN
2008
careHPV® development sponsored by the Gates Foundation
2010
CE-IVD certified
2012
CFDA approved
2013
The global launch conference in Beijing
2018
Pre-qualified by WHO
now
Widely used in Asia, Africa, Latin America and other regions
Based on the gold standard hybrid capture technology and using full-length 8,000 base pairs RNA probes, careHPV®Test can detect 14 high-risk HPV subtypes in cervical samples.
careHPV® Test is the first HPV product in China that is pre-qualified by WHO for cervical cancer screening.
careHPV® Test has been extensively clinically validated and the published data has been referenced in the 2023 Guidelines for Cervical Cancer Screening in China.
careHPV® Test is robust, easy-to-use, accurate, and fast turn-around, the only product that can be used in skilled laboratories and low-resource settings (no PCR laboratory and cold chain required).
careHPV® Test has been recommended by WHO and European authorities as the best primary screening tool for cervical cancer prevention while HPV genotyping is still under clinical investigations (2023 Guidelines for Cervical Cancer Screening in China).
careHPV® Test is the first HPV product in China that is pre-qualified by WHO for cervical cancer screening.
careHPV® Test has been extensively clinically validated and the published data has been referenced in the 2023 Guidelines for Cervical Cancer Screening in China.
careHPV® Test is robust, easy-to-use, accurate, and fast turn-around, the only product that can be used in skilled laboratories and low-resource settings (no PCR laboratory and cold chain required).
careHPV® Test has been recommended by WHO and European authorities as the best primary screening tool for cervical cancer prevention while HPV genotyping is still under clinical investigations (2023 Guidelines for Cervical Cancer Screening in China).
Dr. Shi emphasizes the importance of careHPV technology in low-resource regions in THE FOUNDER magazine.
Dr. Shi introduces the innovative careHPV technology in THE SCIENTIST magazine.
Xujing (Julie) Zhu discusses how cervical cancer screening technology can be adapted for women in developing countries on European Biopharmaceutical Review (EBR) magazine.
